Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Spontaneous remission in canine myasthenia gravis
Bayer 2255.jpg © Bayer
Myasthenia gravis is thought to be a rare autoimmune disease in dogs. Canine myasthenia gravis (MG) is used in studies to assess the effect of immunotherapies in this disease in humans. These results question the value of these studies.

The natural course of autoimmune canine MG was determined in 53 dogs with muscular weakness and a positive acetylcholine receptor antibody titer. Dogs were treated with anticholinesterase therapy, without immunosuppression.

Spontaneous clinical and immunologic remission occurred in 47 of 53 dogs within an average of 6.4 months. Neoplasia was identified in the six dogs that did not spontaneously remit. This study questions the value of using canine MG in studies designed to assess the effect of immunotherapies.

Source: Shelton GD, Lindstrom JM. (2001): Spontaneous remission in canine myasthenia gravis: Implications for assessing human MG therapies. In: Neurology 2001 Dec 11;57(11):2139-2141




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Novel intratumoral therapy in canine transmissible venereal tumourmembers
Canine transmissible venereal tumour (CTVT) is a naturally occurring contagious neoplasm of dogs located mainly on the external genitalia of both sexes. The course of vincristine chemotherapy, the most effective and practical therapy, is affected by the immune status of the host. The aim was to investigate recombinant human interferon alpha‐2a (rhIFNα‐2a) and vincristine for treatment of CTVT.

  • Long-term outcome of dogs with primary immune-mediated thrombocytopeniamembers
  • Insulin treatment and IGF-I in cats with diabetes mellitusmembers
  • Color doppler ultrasound in neoplastic and non-neoplastic canine testicles members
  • Computed tomographic arthrography of the canine shoulder joint members
  • Prognostic scoring system for dogs managed with hemodialysismembers
  • Sonography vs percutaneous palpation to identify targeted thoracolumbar intervertebral disc spacesmembers
  • Distribution of alveolar-interstitial syndrome in dogs and cats with respiratory distress members
  • Disorders of sex development in catsmembers
  • Core ocular surface microbiome in dogsmembers
  • ACVIM small animal consensus statement on safe use of cytotoxic chemotherapeutics members
  • MRI imaging of masticatory muscles in basset houndsmembers
  • Mucosal microbiota, gastrointestinal inflammation and small cell intestinal lymphoma in cats members


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved